Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
Hims & Hers shares have surged over 200% this year, putting the company on track for its best annual performance since going public.$Hims & Hers Health (HIMS.US)$ shares are trading 22% higher on Monday afternoon. Its strength has been attributed to President-elect Donald Trump's plans to nominate Marty Makary to lead the FDA.
$Hims & Hers Health (HIMS.US)$ 截至星期一下午，股票交易上涨了22%。这种强劲表现归因于当选总统特朗普计划提名马蒂·马卡里担任FDA的领导。
Bloomberg reported earlier that a Hunterbrook Media report shared the connection of Makary and Hims & Hers: Makary is an executive at Sesame Inc., a startup that also offers compounded GLP-1 weight loss drugs.
彭博社早些时候报道称，Hunterbrook Media的报告分享了马卡里与Hims & hers的联系：马卡里是Sesame Inc.的高管，该初创公司还提供复合GLP-1减肥药概念。
Hunterbrook Capital, the hedge fund behind the report, revealed it is now holding long positions in Hims shares, reversing its June short bet, which had focused on the company’s online sales of compounded GLP-1 injections.
报告背后的对冲基金Hunterbrook Capital透露，它现在持有Hims股票的多头头寸，逆转了6月时专注于该公司在线销售复合GLP-1注射剂的空头押注。
Hims & Hers shares have surged over 200% this year, putting the company on track for its best annual performance since going public.
Hims & hers的股票今年暴涨超过200%，使公司有望实现自上市以来最佳年度业绩。
However, Wall Street remains cautious, with more than half of analysts covering the stock issuing hold or sell ratings, according to Bloomberg data. Nearly 40% of analysts have a buy recommendation for the shares.
然而，华尔街依然保持谨慎，超过一半的分析师对该股给予持有或卖出的评级，彭博社数据显示，近40%的分析师对该股票发出了买入推荐。
